Sumis Partners Launches, Uniting Industry Leaders to Redefine Life Sciences Consulting
illi News/10301202

INCLINE VILLAGE, Nev. & BOSTON - illiNews -- Sumis Partners, Inc. announces its launch as a next-generation professional services platform designed to meet the evolving demands of the life sciences, healthcare, and public health sectors. The firm brings together a network of senior-led, specialized teams operating across geographies and disease areas, offering clients breadth, speed, and precision without the inefficiencies of traditional consulting models.

Rooted in three principles—senior-led execution, tailored engagements, and a focus on measurable outcomes—Sumis is purpose-built for biopharma and health organizations facing complex challenges and high-stakes decisions in a rapidly evolving environment. The firm offers services across the full product lifecycle, including new product planning, business development, market access, commercialization, evidence generation, health policy, and digital/AI transformation.

"Sumis is not a repackaged legacy firm or investor-led roll-up looking for growth metrics. It's a ground-up structure built by operators, advisors, and strategists who have led launches, built systems, and solved the kinds of problems our clients face every day, oriented around the success of our customers and their products," said Jennifer Hinkel, President of Sigla Sciences, a Sumis Partners Affiliate, and one of the Sumis Partners founders.

Within a lean model, Sumis deploys highly-specialized, expert-driven teams with transparent pricing, flexible project scoping, and a digital-native approach. The firm supports clients in North America, Europe, and global launch markets through integrated offerings that span strategy, analytics, medical affairs, commercial, and creative.

More on illi News

• Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
• Bak Brothers, Inc. Expands Exterior Remodeling Services to La Grange, IL
• AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
• The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
• Veterans and Young Job Seekers Get a Boost Through Mentor Agile's Expanded WIOA Support Program

By combining capabilities, Sumis Partners is equipped to support clients of all sizes in navigating reimbursement complexity, scaling evidence generation, accelerating launch planning, and building policy-aligned access strategies—all with senior accountability and no junior handoffs.

"Sumis is a purpose-built alliance designed for modern biopharma and health tech challenges," said Dr. Cory Kidd, founder of Advient Advisors, a Sumis Partners Affiliate, and one of the Sumis Partners founders. "Sumis is about impact, not process. We work shoulder-to-shoulder with our clients to accelerate outcomes and remove barriers."

"Joining Sumis Partners amplifies Metli's mission to redefine public health consulting through innovation, creativity, and deep expertise in patient-centered solutions. Our combined strengths empower us to deliver unmatched value in health equity, real-world evidence, and AI-driven engagement, ultimately transforming how organizations achieve meaningful health outcomes globally. Sumis is grounded in the fact that we are here for the patient," said Dr. Taylor Hirschberg, CEO of Metli, a Sumis Partners Affiliate, and one of the Sumis Partners founders.

Affiliate Firms & Capabilities

Sigla Sciences specializes in data-driven, technology-enabled market access, health economics, and launch strategy for biopharma, diagnostics, and devices. Known for its work in oncology, rare disease, immunology, and CGTs, Sigla applies strategic foresight, scenario planning, and predictive analytics to help innovators navigate policy and access complexity for successful product launches. Learn more at siglasciences.com.

Metli combines health equity, global public health, and creative strategy with deep capabilities in qualitative research, epidemiology, patient-centered design, and AI-enabled stakeholder engagement. The firm excels in integrating patient-reported outcomes (PROs) and real-world evidence (RWE) to drive high-impact programs across disease areas, with expert depth in infectious disease, oncology, health equity, and population health. Where imagination sparks discovery. Learn more at metliconsulting.com.

More on illi News

• Build. Repair. Refresh – Summer Pond Projects Are in Full Swing!
• Lake Street Capital Partners Establishes New Residential Services Platform HighPoint Exterior Home Services by Partnering with Choufani & Bailey Roofing & Restoration
• $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
• Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
• Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids

Rapid Commercialization Partners (RCP) provides commercialization and launch support to clinical-stage biotechs, delivering executive-level fractional leadership across strategy, marketing, and operations. RCP emphasizes acceleration, discipline, and long-term value creation. Learn more at rcpbio.com.

Advient Advisors, founded by MIT Media Lab PhD Dr. Cory Kidd, delivers strategic AI consulting and organizational readiness programs for life sciences, healthcare, and other complex and highly-regulated industries. The firm blends technical depth with behavioral science to enable sustainable digital transformation. Learn more at advientadvisors.com.

Solem Global operates across the U.S. and Europe to drive global launch readiness, pricing, distribution, and commercialization strategy. With operational teams in Washington DC, Madrid, and Münster, Solem offers in-country execution to match its senior-level strategic depth. Learn more at solemglobal.com.

Presley Global Management offers executive-level guidance to life sciences companies navigating FDA-regulated markets, combining commercialization expertise with implementation pathways designed to de-risk U.S. entry and accelerate ROI.